1. Home
  2. COF vs VRTX Comparison

COF vs VRTX Comparison

Compare COF & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital One Financial Corporation

COF

Capital One Financial Corporation

HOLD

Current Price

$196.24

Market Cap

139.8B

Sector

Finance

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$496.14

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
COF
VRTX
Founded
1988
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
139.8B
115.7B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
COF
VRTX
Price
$196.24
$496.14
Analyst Decision
Strong Buy
Buy
Analyst Count
16
27
Target Price
$269.31
$526.79
AVG Volume (30 Days)
4.6M
1.3M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
1.53%
N/A
EPS Growth
N/A
836.54
EPS
N/A
15.32
Revenue
N/A
$2,488,652,000.00
Revenue This Year
$95.91
$11.10
Revenue Next Year
$5.17
$10.23
P/E Ratio
$52.03
$31.20
Revenue Growth
N/A
46.20
52 Week Low
$143.22
$362.50
52 Week High
$259.64
$519.68

Technical Indicators

Market Signals
Indicator
COF
VRTX
Relative Strength Index (RSI) 37.88 61.37
Support Level $187.63 $432.09
Resistance Level $202.56 $507.32
Average True Range (ATR) 7.93 13.58
MACD -0.42 1.37
Stochastic Oscillator 22.69 82.14

Price Performance

Historical Comparison
COF
VRTX

About COF Capital One Financial Corporation

Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending provides the majority of the bank's revenue.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: